Form 4: Phathom Pharmaceuticals Director Heidi Fields Reports Stock and Option Grants

Director Heidi Fields reports receiving stock and option grants from Phathom Pharmaceuticals on May 23, 2024.

Summary

• Heidi Fields, a director of Phathom Pharmaceuticals, reported changes in beneficial ownership on May 23, 2024.
• Fields received 10,500 shares of common stock as Restricted Stock Units (RSUs) and disposed of 0 shares.
• These RSUs vest on the earlier of the first anniversary of the grant date or the next annual meeting, contingent on continued service on the board.
• Each RSU represents a right to receive one share of Phathom Pharmaceuticals common stock.
• Fields also received an option to buy 17,500 shares of common stock at an exercise price of $10.30.
• This option also vests on the earlier of the first anniversary of the grant date or the next annual meeting, contingent on continued service on the board.
• Following these transactions, Fields beneficially owns 19,500 shares of common stock and options for 17,500 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, which is generally viewed positively as it aligns director interests with shareholders. The sentiment is neutral to slightly positive.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Future Outlook

The vesting of the RSUs and stock options is contingent upon Fields' continued service on the board, indicating an expectation of ongoing involvement.

Industry Context

Stock and option grants are a common form of compensation for directors, aligning their interests with shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Director compensation packages typically include a mix of cash, stock, and options.
• The specific amounts and vesting schedules vary depending on the company's size, industry, and performance.
• Comparing Phathom Pharmaceuticals' director compensation to that of similar-sized biotech companies would provide a more detailed assessment.

Stakeholder Impact

• The grant of equity to directors can positively impact shareholders by aligning management's interests with long-term value creation.
• The vesting schedule incentivizes the director to remain engaged and contribute to the company's success.

Key Dates